Company Registry

T3D Therapeutics Inc
Profile last edited on: 12/17/2019

Remedial therapeutics for Alzheimer’s disease and other CNS disorders
Year Founded
2013
First SBIR Year
2015
Latest SBIR Award
2016
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

68 TW Alexander Drive PO Box 13628
Research Triangle Park, NC 27709
   (919) 237-4897
   info@t3dtherapeutics.com
   www.t3dtherapeutics.com
Multiple Locations:   
Congressional District:   04
County:   Durham

Public Profile

In 2019, T3D Therapeutics was awarded the first increment of what could be a $9M grant from National Institutes for Aging to fund Phase II clinical trial for the firm's leading candidate, T3D-959, an orally administered daily treatment for Alzheimer’s. T3D has an exclusive, worldwide license for T3D-959 and structurally-related molecules -- an optimal therapeutic for the treatment of Alzheimer’s Disease (AD). TT3D-959 has advanced successfully through Phase 1 human clinical trials showing evidence of pharmacological activity and no reported safety concerns. This drug has the potential to be a transformational therapy by acting in a multi-faceted manner to improve most of the defects (pathologies) of AD, including a likely ‘trigger’ for the disease, insulin and IGF-resistance. This potential disease-modifying therapeutic is an orally-delivered, once a day medicine for AD patients with mild to moderate disease severity and potentially patients with mild cognitive impairment (MCI). Additionally, the mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) disorders. The Company’s vision is to develop the product through a series of three stage gates culminating in a Phase 2b clinical trial. Each stage gate provides a potential opportunity for an investor exit through sale or out-licensing of T3D-959 to a large pharmaceutical company. Development is executed in a capital-efficient, virtual operation that minimizes infrastructure and personnel costs.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  John Didsbury -- President, CEO and Founder

  Stanley D Chamberlain -- Chief Scientific Officer

  Hoda Gabriel -- Sr. Director, Clinical Development

  Warren Strittmatter -- Chief Medical Officer

  Ching-Hong Yang --